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Abstract
Background: The number of promising therapeutic interventions for Duchenne Muscular Dystrophy (DMD) is increasing
rapidly. One of the proposed strategies is to use drugs that are known to act by multiple different mechanisms including
inducing of homologous fetal form of adult genes, for example utrophin in place of dystrophin.
Methodology/Principal Findings: In this study, we have treated mdx mice with arginine butyrate, prednisone, or a
combination of arginine butyrate and prednisone for 6 months, beginning at 3 months of age, and have comprehensively
evaluated the functional, biochemical, histological, and molecular effects of the treatments in this DMD model. Arginine
butyrate treatment improved grip strength and decreased fibrosis in the gastrocnemius muscle, but did not produce
significant improvement in muscle and cardiac histology, heart function, behavioral measurements, or serum creatine
kinase levels. In contrast, 6 months of chronic continuous prednisone treatment resulted in deterioration in functional,
histological, and biochemical measures. Arginine butyrate-treated mice gene expression profiling experiments revealed that
several genes that control cell proliferation, growth and differentiation are differentially expressed consistent with its
histone deacetylase inhibitory activity when compared to control (saline-treated) mdx mice. Prednisone and combination
treated groups showed alterations in the expression of genes that control fibrosis, inflammation, myogenesis and atrophy.
Conclusions/Significance: These data indicate that 6 months treatment with arginine butyrate can produce modest
beneficial effects on dystrophic pathology in mdx mice by reducing fibrosis and promoting muscle function while chronic
continuous treatment with prednisone showed deleterious effects to skeletal and cardiac muscle. Our results clearly indicate
the usefulness of multiple assays systems to monitor both beneficial and toxic effects of drugs with broad range of in vivo
activity.
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Introduction
Long-term development of definitive treatments for DMD,
addressing the problem of the primary defect by gene supplemen-
tation, repair or compensation are all relatively time consuming
processes, especially in the eyes of affected boys and their families.
For this reason, there is considerable interest in testing potentially
palliative agents that are currently registered for clinical
application. Since such agents do not address the primary cause
of the defect, and our understanding of the pathology downstream
of this primary cause remains inadequate, they have to be judged
empirically in terms of beneficial and deleterious effects.
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11220Candidates for this class of therapeutic agent are selected largely
for their activities in other pathological conditions and our
speculations as to other actions on what we suspect to be the
main pathogenic pathways in DMD. Given the uncertainties
involved, it is important to scan for indications of beneficial effect
and, perhaps more importantly, for signs of deleterious side effects
across as wide a range as possible of outcome measures. In the case
of DMD, most primary investigations of putative therapeutic
agents are conducted on the mdx mouse, because of its ease of
production and maintenance, but most such studies concentrate
on a small number of measures of outcome. In an attempt to
remedy this, we have developed a protocol that encompasses a
broad set of assessment criteria by which to detect subtle but
significant effects of test agents on functional outcome measures in
the mdx mouse, so arranged as to signal both desirable and
undesirable effects of any given treatment regime [1]. Here we
apply this protocol to a comparison of two different agents known
or reputed to influence the course of the myopathy arising from
dystrophin deficiency. First, prednisone which has well-recognized
therapeutic value in DMD via as yet ill-understood mechanisms
but which is associated with significant side effects that
countermand its use in some individuals. Second, arginine
butyrate, which has been postulated to exert beneficial effects
via a spectrum of activities associated with the histone deacetylase,
mediated control of expression of a variety of genes and also to
provide a substrate for NOS signaling pathways. On this study we
have used a wide variety of behavioral, functional, histological,
biochemical, imaging and molecular assays to comprehensively
assess the effects of these two drugs either alone or in combination
in mdx mouse model of muscular dystrophy, We found that
arginine butyrate treatment improved hindlimb grip strength and
decrease fibrosis in the gastrocnemius but did not produce any
significant improvements in muscle histology, behavioral mea-
surements, or serum creatine kinase (CK) levels. In contrast, 6
months of chronic continuous treatment with prednisone as
opposed to daily administration of a single dose resulted in
deterioration in functional, histological, and biochemical mea-
sures. Our gene expression profiling experiments pointed to
significant alterations in the expression of genes that control cell
growth, differentiation, signaling, inflammation, and fibrosis in
skeletal muscle as a result of arginine butyrate and prednisone
treatment. Our results indicate the usefulness of multiple assays
systems monitoring both beneficial and toxic effects of drugs with
broad range of activity.
Materials and Methods
Animal Care
All mice were handled according to the local Institutional
Animal Care and Use Committee guidelines. C57BL/10ScSn-
Dmd
mdx/J (mdx) and C57BL/10ScSn (BL10) female mice weighing
20–30 g (8- to 10-week-old) were purchased from The Jackson
Laboratory (Bar Harbor, ME). All mice were housed in an
individually vented cage system with a 12-h light-dark cycle and
received standard mouse chow and water ad libitum. Mice were
rested at least 10–14 days before acclimation was begun and
baseline readings were obtained.
Study design
The study involved four groups of 15 animals each: (a) a control
group dosed with 0.9% NaCl (I.P) (the vehicle for the arginine
butyrate preparation), (b) a group receiving arginine butyrate at
250 mg/kg/day I.P., (c) a group treated with prednisone at 1 mg/
kg/day (slow-release subcutaneous pellets), and (d) a group
(referred to as the combination-treated group) receiving arginine
butyrate at 250 mg/kg/day I.P and prednisone at 1 mg/kg/day.
Mice were treated for 6 months, beginning at 3 months of age for
5 days each week (Monday-Friday) for 6 months. The arginine
butyrate solution was stored at room temperature. Prednisone
slow-release subcutaneous tabs (Innovative America, Inc) are
available as a 90-day release formulation with a daily slow release
of 1 mg/kg. Two tabs were used per mouse, with the second tab
being implanted after 3 months.
Treadmill exercise
Mice were subjected to a 30-min run on a horizontal treadmill
(Columbus Instruments, Columbus, OH) at 12 m/min to unmask
the mild dystrophic phenotype. The test was performed during the
morning hours twice weekly over the course of the 6 months,
except on those days on which functional data were obtained.
Rotarod test
Rotarod tests were performed as described previously [1,2]:
Mice were trained on the Rotarod (UgoBasile, VA, Italy) for 2
days before data collection. Each trial was done twice a day, with a
2-hour interval between sessions, for 3 consecutive days. The
latency to fall (seconds) was recorded, and all six scores were
averaged for each mouse. The averaged data were expressed as
latency to fall (seconds) for each mouse.
Grip strength test
Grip Strength was assessed using a grip strength meter
consisting of horizontal forelimb mesh and an angled hindlimb
mesh (Columbus Instruments, Columbus, OH). Five successful
hindlimb and forelimb strength measurements within 2 minutes
were recorded and normalized to body weight as previously
described [1].
Behavioral activity measurement
Open field activity was measured using an open field Digiscan
apparatus (Omnitech Electronics, Columbus, OH) as described
previously [1,3]. All mice were acclimated for 60 minutes before
actual data collection. Data were collected every 10 minutes over a
1-hour period each day for 4 consecutive days. Results were
calculated as means6SE of all recordings.
Echocardiography
Five mice per treatment group were scanned at 9 months of age.
Mice were anesthetized with 1–2% isoflurane in 100% oxygen and
scanning was performed over 20 minutes using a high frequency
ultrasound probe (RMZ 702a, Vevo 660, VisualSonics, Toronto,
Canada) as previously described [1,4]. Qualitative and quantita-
tive measurements were made offline using analytic software
(VisualSonics, Toronto, Canada).
Histological evaluations
At the end of the trial, all mice were euthanized, and tissue
samples were taken for extensive testing as described below. A
portion of each of the dissected muscles (e.g., gastrocnemius,
diaphragm, and heart) was kept in formalin for H&E and Sirius
Red staining. The remaining portion of each tissue was embedded
in OCT compound and frozen in isopentane chilled in liquid
nitrogen. Five non-overlapping representative fields of the tissue
were imaged under a light microscope at an objective of 406(high
power field) and a digital image obtained using computer software
(Olympus C.A.S.T. Stereology System, Olympus America Inc.,
Center Valley, PA). The digital images were loaded into Image J
Preclinical Trials in mdx
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centralized nuclei, peripheral nuclei and total number of cells with
centralized nuclei were counted and analyzed for comparison
between treatment groups. Fibers showing degeneration (loss of
striations/homogenous appearance of fiber contents) or regener-
ation (basophilic cytoplasm, large peripheral, or central nuclei with
prominent nucleoli) and inflammatory foci per field were assessed
in a blinded fashion as previously described [1].
Fiber diameter measurements
Briefly, serial 8–10 mm thick frozen sections were cut using an
IEC Minotome cryostat, mounted to super frost plus slides (Fisher
Scientific) and fixed in cold acetone for 10 minutes. Sections were
blocked using 100 ml 10% horse serum and incubated with
primary Laminin antibody (rat anti ms Laminin). After two washes
of PBS sections were applied with Goat anti-rat Alex Fluor 488
(Green). After two washes of 5 minutes with 16TBS slides were
mounted using Vectashield mounting medium with DAPI.
The tissue was imaged under a fluorescent microscope at an
objective of 206and a digital image obtained. The digital images
were processed using Axiovision software and minimal feret’s
diameter was measured. To obtain the actual micron size we set a
scale using a microscope scale (Graticules LTD Tonbridge, Kent,
England) 10060.01=1 mm. The data were ranked according to
size, the ranks were then normalized to sample size (rank number/
total sample number) and the normalized rank was plotted on the
vertical axis against fiber size on the horizontal axis. Kolmogorov-
Smirnov test was used to assess difference among fiber size
distribution.
Fibrosis measurements
Paraffin sections were stained with Sirius Red stain [Sigma-
Aldrich, St. Louis, MO], and counter-stained with hematoxylin to
visualize nuclei. The dye molecule intercalates into the tertiary
groove in the structure of collagen types I and III and imparts a
pink stain to most tissues when observed under white light. The
tissue was imaged under a light microscope using a 46objective,
and a digital image was obtained using computer software
(Olympus C.A.S.T. Stereology System, Olympus America Inc.,
Center Valley, PA). The digital images were processed using
Image J (NIH), with an additional threshold color plug-in to
process .jpeg images. The percentage of the fibrotic area
corresponding to the area stained in red was compared to the
total area of the tissue section, and the results were expressed as %
non-muscle area.
mRNA expression profiling
For RNA isolation, gastrocnemius tissue (from 4 mice/group,
totaling 16 mice) was frozen in isopentane cooled with liquid
nitrogen. The tissue was placed into a tube with 1 ml of Trizol and
homogenized. The total RNA was isolated and then cleaned using
the Qiagen RNeasy Mini kit (Qiagen, Valencia, CA) according to
the manufacturer’s instructions. The resulting total RNA was
checked on a gel for RNA integrity and quantified using a
Nanodrop ND-100 Spectrophotometer (Nanodrop Technologies,
Wilmington, DE).
Gene expression profiling was carried out as described
previously; using GeneChip mouse expression set 430 (Affymetrix
430 2.0, Santa Clara, CA) [5]. Probe set analysis was done using
Microarray Suite, version 5.0. The signal intensity values (absolute
analyses) of the probe sets were then loaded into GeneSpring
(Silicon Genetics, Redwood City, CA) for further analysis. A t-test
was performed to test the significance of any differences between
the drug-treated and control group results.
Western blotting
Total protein was extracted from frozen gastrocnemius muscle
by placing the tissue in NP40 lysis buffer. Samples were run on a
4–12% BIS-TRIS 15-well gel (Invitrogen) for 2–2.5 h at 200 V
and transferred onto a nitrocellulose membrane for 2 h at
300 mA. Following transfer, the blot was stained with Ponceau
red to determine the efficiency of the transfer. The blot was then
blocked in 5% milk for 1 h and incubated with anti-utrophin
(1:100) (NCL-DRP2, Novocastra) overnight at 4uC, washed five
times for 6 min each with Tris buffered saline, and incubated with
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG
secondary antibody (1:3000) for 1 h at room temperature.
Following another series of washes with TBST, the blots were
incubated for 1 min using ECL (Amersham), and the blots were
developed. The blots were then stripped and blotted for beta-
tubulin (55 kDa) to assess equal gel loading. The autoradiograms
were scanned using an Arcus II scanner, and volume analysis was
carried out using Quantity One software (Bio-Rad Discovery
Series). The ratio of utrophin to beta-tubulin was calculated for
each group of mice.
CK determination
Blood was collected by heart puncture immediately after
euthanasia with carbon dioxide: 250 mL of blood was collected
into Eppendorf tubes with no additive for serum separation, and
CK determination was performed using a standard spectropho-
tometric method. Assays were carried out using the enzyme-
coupled assay reagent from Fisher Scientific (CK10) according the
manufacturer’s instructions. Absorption at 340 nm was measured
every minute for 2 min at 37uC to calculate the enzyme activity.
Duplicate measurements were done on each serum sample.
Statistical analysis
Statistical analysis was performed by Student t-test to analyze
the difference between two groups, One-way analysis of variance
followed by Bonferroni post hoc test to compare the difference
within groups and two-way analysis of variance to compare
differences among groups and time. A total of eight histology
measurements (degeneration fibers, regenerating fibers, inflam-
mation, calcification, and central and peripheral nuclei) were
compared between mdx and BL10 mice. Comparisons were made
using Poisson regression or using negative binomial regression
where the Poisson model did not fit the data due to over
dispersion.
The Kolmogorov-Smirnov test for equality of distribution was
used to compare 6 parameters between mice under different
treatment conditions (saline treated, arginine-butyrate treatment,
prednisone treatment, and a combination of prednisone and
arginine-butyrate). Each treatment was compared in a pair-wise
fashion and the resulting p-values were adjusted for multiple
comparisons using the Sidak method. A nominal p-value of 0.05
was considered statistically significant. All analyses were done
using Stata V10 (College Station, TX). The differences were
considered significant at a p value of ,0.05.
Results
Effect of 6 months treatment with arginine-butyrate,
prednisone, or a combination of arginine butyrate and
prednisone on mdx mice
Effect on body weight. 6 months administration of arginine
butyrate to mdx mice did not significantly change their overall
body weight and growth pattern when compared to saline-treated
Preclinical Trials in mdx
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a combination of prednisone and arginine butyrate resulted in a
significant decline in body weight during the first 2 months of
treatment. The body weight gradually increased over the next 4
months, but was significantly lower than that of arginine butyrate-
or saline-treated mice at 9 months of age (6 months of treatment;
Figure 1). We then compared this data with age and sex matched
BL10 wild type data that was previously published [1]. Saline and
arginine butyrate treated mdx mice showed an increase of 103.12%
and 100.93% respectively whereas prednisone and combination
treated group displayed 84.7% and 86.33% of normal body weight
respectively. This decrease in body weight was also reflected in a
significant decrease in gastrocnemius muscle weight in the
prednisone (absolute)- and combination-treated groups (absolute
and normalized), than in arginine butyrate- and saline-treated
groups (Supplementary Table S1).
No statistically significant differences were observed in the
weight of heart tissue of the drug -and saline -treated groups but
normalization showed significantly increased heart mass in
prednisone and combination treated groups. The weight of soleus
was significantly increased in arginine butyrate treated (absolute)
group in comparison to saline treated group, however normalized
values of soleus weights significantly increased in all treatment
groups in comparison to saline treated group (Supplementary
Table S1). We also observed significant decrease in spleen weights
(absolute) in all three drug-treated groups with the exception of
combination (normalized) group in comparison to the saline-
treated mice (Supplementary Table S1).
Effect on behavioral measurements. Both the forelimb
and hindlimb grip strength decreased in all groups by the end of
treatment, at 9 months of age (Figure 2). The arginine butyrate
treated group showed a significant improvement in unadjusted
forelimb at 5 months compared to saline treated (0.126
0.01vs.0.1160.01 p=0.03). The rate of decline in the
unadjusted forelimb strength was slower in the arginine
butyrate-treated group than in the prednisone-, combination-, or
saline-treated groups (Figure 2A). On the other hand hindlimb
strength showed an increment from 3 months to 5 months and a
subsequent decline at 9 months in saline and arginine butyrate
treated animals, at which point arginine butyrate showed
significant better strength than saline treated (0.1660.01 vs.
0.1860.01, p=0.002). Prednisone and Combination treated
groups showed a significant decline in hindlimb strength when
compared to saline treated animals (p=0.01, p=0.04 respectively)
(Figure 2B). However, normalization of forelimb strength with
body weight revealed a slower decline in strength in the arginine
butyrate-, prednisone-, and combination-treated groups than in
the saline-treated group (Figure 2C). Again, arginine butyrate
treated group showed significantly better strength than saline at 5
months (p=0.01). The unadjusted hind limb strength was lower at
9 months of age in the prednisone- and combination-treated
groups than in the arginine butyrate- or saline-treated groups. All
the drug-treated mice appeared to show a slower decline than did
the saline-treated control group at 9 months of age (Figure 2D),
and arginine-butyrate treated group presented with a significant
difference in strength at 9 months (5.9860.67 vs.6.6260.44
p=0.004). We have compared this data with previously published
BL10 wild type mice grip strength data and treatments resulted in
61.62% (Saline), 66.91% (Arginine butyrate), 75.32% (Prednisone)
and 73.1%1 (Combination) change in forelimb grip strength and
65.16%% (Saline), 72.14% (Arginine butyrate), 72.99%%
(Prednisone) and 72.42% (Combination) change with respect to
BL10 wild type mice. Latency to fall (sec) on the Rotarod test is
used to assess motor coordination and strength. All the treatment
groups showed a decreased time on the Rotarod with increasing
age (Supplementary Figure S1A). Similarly, in an analysis of
behavioral measurements such as horizontal activity, vertical
activity, and total distance using an open field activity (Digiscan)
chamber, showed no statistically significant differences
(Supplementary Figure S1B–1D).
Effect on histology. Examination of Hematoxylin and Eosin
(H&E)-stained sections of gastrocnemius muscle of arginine
butyrate-treated mice showed no significant change in total
number of fibers, number of total central nuclei (refer to the
amount of regeneration in a field) and number of fibers with
central nuclei (fibers with centralized nuclei refers to cells
undergoing regeneration cycle) number of degenerating fibers,
regenerating fibers, peripheral nuclei, inflammatory loci and
number of peripheral nuclei per high power field in comparison
to saline treated group (Table 1).
Since we noticed significant differences in body weight as well as
muscle weight we decided to measure the fiber size distribution in
all 4 groups of mice. The highest fiber size distribution
(supplementary Figure S2) difference among treatment groups
was found between 35 and 65 microns. Saline treated group
showed the larger fiber sizes than prednisone and combination
treated groups while arginine butyrate treated group showed an
intermediate size between saline and prednisone or combination
treated groups (Table 2).
We then further evaluated the heart, diaphragm and gastroc-
nemius muscle of these mice for fibrosis by staining the tissues with
Sirius Red. Fibrosis was significantly decreased in gastrocnemius
muscle of arginine treated mice (p=0.04) compared to saline
treated groups (Figure 3) There were no significant changes in
collagen content of hearts in the arginine butyrate-treated hearts.
However, the amount of fibrosis observed in the heart was
significantly higher in the prednisone- and combination-treated
groups compared to saline treated group (Figure 4) Diaphragm
showed increased collagen content in arginine butyrate group
(p=0.004) (Figure 5) Comparison of serum Creatine kinase levels
between the groups showed no statistically significant differences
(data not shown).
Figure 1. Effect of treatments on body weight. mdx mice received
saline (solid black), arginine butyrate (solid grey), prednisone (broken
black), a combination of arginine butyrate and prednisone (broken
gray), for 6 months, beginning at 3 months of age. Body weights were
obtained at 3 (baseline), 5, and 9 months of age. Error bars indicate +/2
1 SD. ** p=,0.001.
doi:10.1371/journal.pone.0011220.g001
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evaluated the heart function of the drug-treated and saline control
groups by echocardiography. No statistically significant changes
occurred in the ejection and shortening fraction of arginine
butyrate-treated group (Figure 6). This result is in contrast to the
significant decrease in both ejection and shortening fractions that
was seen in the prednisone treated group (Figure 6).
Effect on utrophin expression. Since arginine butyrate is
known to induce the expression of fetal genes, including utrophin,
we used Western blotting to detect utrophin in skeletal muscle
Figure 2. Effect of treatments on forelimb and hind limb grip strength. Grip strength was measured using a grid at 3, 5, and 9 months of
age. a) Maximal forelimb grip strength, b) The maximal hind limb grip strength, c) The normalized maximal forelimb strength, d) The normalized
maximal hind limb strength of all the groups. Mdx mice received saline (solid black), arginine butyrate (solid grey), prednisone (broken black), a
combination of arginine butyrate and prednisone (broken gray), for 6 months, beginning at 3 months of age. Parameters were obtained at 3
(baseline), 5, and 9 months of age. Error bars indicate +/2 1 SD. * p=,0.01, ** p=,0.001, *** p=,0.0001.
doi:10.1371/journal.pone.0011220.g002
Table 1. Comparison of histological parameters in the gastrocnemius muscle of treatments in mdx mice.
Histology measurement # FP0023 (N=8) Combination (N=7) Prednisone (N=8) Untreated (N=8)
Mean±SEM Mean±SEM Mean±SEM Mean±SEM
Number of fibers/field 78.6166.62 70.9066.08 69.0668.24 69.2765.05
Central Nuclei/field 54.3163.81 46.1963.79 46.5663.76 46.6163.01
Peripheral Nuclei/field 73.1664.04 72.7266.02 78.7765.78 72.6164.62
Number of fibers with Centralized nuclei/field 37.8562.55 33.1362.26 33.1761.84 33.2062.35
Degenerating fibers/field 8.2562.84 10.2562.53 11.3862.41 6.5061.71
Regenerating fibers/field 10.1363.62 7.2562.15 5.3862.93 9.8862.70
Inflammatory foci/field 2.1360.85 2.3861.95 3.2561.52 1.1360.55
# data was collected from 5 non-overlapping field from each sample and average of all samples within a group; * Analyzed as log (central/peripheral) using linear
regression.
doi:10.1371/journal.pone.0011220.t001
Preclinical Trials in mdx
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variations in the utrophin expression among the arginine butyrate
containing groups (Figure 7). Normalization of utrophin
expression to tubulin expression, showed a 28% increase in the
utrophin expression in the arginine butyrate-treated group and the
combination-treated group (Figure 7).
Effect on mRNA profiling. mRNA expression profiling of
gastrocnemius muscle from the drug-treated and saline control
groups was performed using Affymetrix gene chips. To interpret
the microarray data, we have used multiple probe set algorithms
(MAS5.0, dCHIP difference model, PLIER). We have analyzed
the data using GeneSpring software. Unsupervised hierarchical
clustering showed arginine butyrate treatment drastically altered
gene expression in skeletal muscle of dystrophic mice, followed by
combination group and prednisone treated groups in comparison
to saline treated group (Figure 8). Initially, we looked for genes that
showed a two-fold change in expression, with a p-value of 0.01 and
the drug treated groups were compared to the saline-treated
group. We found that 1515 genes were significantly altered (453
upregulated and 1062 downregulated) in the arginine butyrate-
treated group, 136 (72 upregulated and 64 downregulated) in the
prednisone-treated group, and 261 (102 upregulated and 159
Table 2. Effect of treatments on muscle fiber size: Kolmogorov-Smirnov equality-of-distributions test.
Group Comparison P-value P-value adjusted for multiple comparisons
Combination vs. AB 0.004 0.02
Combination vs. Prednisone NS NS
Combination vs. Saline ,0.001 0.001
AB vs. Prednisone NS NS
AB vs. Saline 0.03 NS
Prednisone vs. Saline 0.003 0.01
doi:10.1371/journal.pone.0011220.t002
Figure 3. Effect of treatments on gastrocnemius collagen content. Sirius Red staining of formalin fixed gastrocnemius sections from four
groups of mice. A representative picture of each group is shown (A–D). Saline treated (A), arginine butyrate treatment (B), prednisone- (C) and
combination-treated groups (D). Quantitation of fibrosis (% fibrosis) was carried out using the ImageJ program.
doi:10.1371/journal.pone.0011220.g003
Preclinical Trials in mdx
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expressed genes were unique to a particular treatment group (e.g.,
1461 genes for arginine butyrate, 103 for prednisone, and 217 for
the combination treatment), and others were shared between
groups (e.g., the arginine butyrate set shared 20 genes with the
prednisone set and 31 genes with the combination set; the
combination set shared 10 genes with the prednisone set; 3 genes
were shared by all three groups).
We found that genes that participate in multiple cellular
activities such as focal adhesion, gap junction, hedgehog signaling
pathway, Wnt signaling pathway, calcium signaling pathway, G
protein signaling, striated muscle contraction, cell cycle, MAPK
signaling pathway, mRNA processing binding reactome, cytokine-
cytokine receptor interaction, adipocytokine signaling pathway,
insulin signaling pathway, Jak-STAT signaling pathway, mTOR
signaling pathway, regulation of actin cytoskeleton, inositol
phosphate metabolism, glycan structures – biosynthesis, fatty acid
biosynthesis, TGF-beta signaling pathway, PPAR signaling
pathway, oxidative phosphorylation, folate biosynthesis, electron
transport chain, aminoacyl-tRNA biosynthesis are differentially
expressed upon arginine butyrate treatment clearly indicating
HDAC inhibitory activity of butyrate [6]. Whereas prednisone
affected relatively less number of pathways that control immune
functions, cell communication, cytokine-cytokine receptor, Wnt
signaling pathway MAPK signaling pathway VEGF signaling
pathway, GnRH signaling pathway, arachidonic acid metabolism,
biosynthesis of steroids as well as carbohydrate and amino acid
metabolism pathways. The combination treated group affected
genes that control Wnt signaling pathway, MAPK signaling
pathway, regulation of actin cytoskeleton, purine metabolism,
Folate biosynthesis, cell communication, ECM-receptor interac-
tion, Sphingolipid metabolism, PPAR signaling pathway, cell
cycle, glycan structures – biosynthesis, glycerophospholipid
metabolism, SNARE interactions in vesicular transport, and
hedgehog signaling pathway. Above pathways are clearly affect
disease progression and severity dystrophic skeletal muscle by
controlling muscle inflammation, fibrosis, muscle growth and
regeneration (supplementary Table S2)
Discussion
From the time of the discovery and characterization of the gene
responsible for Duchenne muscular dystrophy, it was clear that
rectifying the primary defect was going to be a challenge. Not only
is it by far the largest gene known; too large to be encapsulated in
the main viral vectors currently under consideration[7], but also
the predominantly affected tissues, skeletal and cardiac muscle
cells, are not simple targets. Skeletal muscle, especially, presents
the problem of being the most abundant tissue in the body and
being so widely and diffusely distributed that the blood vascular
Figure 4. Effect of treatments on heart collagen content. Sirius Red staining of formalin fixed heart sections from four groups of mice. A
representative picture of each group is shown (A–D). Saline treated (A), arginine butyrate treatment (B), prednisone- (C) and combination-treated
groups (D). Quantitation of fibrosis (% fibrosis) was carried out using the ImageJ program.
doi:10.1371/journal.pone.0011220.g004
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therapeutic agent. Although both tissues are heavily vascularised,
there are no helpful features such as endothelial fenestrae that
might provide ready access of blood-borne agents to the muscle
fiber that is the target of therapy. While genetic manipulations
such as exon skipping have brought us to the verge of therapeutic
success in the animal models, none has yet attained a level of
efficiency to permit its immediate therapeutic application. In the
meantime, there is a need for interim palliative treatments to halt
or slow the progress of the disease. Such treatments are aimed at
what we perceive to be the pathological pathways downstream of
the primary defect, and because we are uncertain of the part
Figure 5. Effect of treatments on diaphragm collagen content. Sirius Red staining of formalin fixed diaphragm sections from four groups of
mice. A representative picture of each group is shown (A–D). Saline treated (A), arginine butyrate treatment (B), prednisone- (C) and combination-
treated groups (D). Quantitation of fibrosis (% fibrosis) was carried out using the ImageJ program.
doi:10.1371/journal.pone.0011220.g005
Figure 6. Effect of treatments on cardiac function. Cardiac function was evaluated by echocardiography at the end of the trial. Both the
ejection and shortening fractions (%) were evaluated. Error bars indicate +/2 1 SD. **p=,0.01.
doi:10.1371/journal.pone.0011220.g006
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in e.g. the inflammatory response to muscle necrosis, lies, it is
important to take the widest possible view of the benefits and
drawbacks of any specific agent and regime of administration.
Accordingly, we have developed a protocol that applies a wide
range of criteria to evaluation of the effects of specific treatment
regimes.
The value of this rationale is well illustrated by the examples of
the two agents we have investigated here. One, prednisone is
currently ‘standard of care’ for those DMD boys who can tolerate
its side effects, but no explanatory mechanism for these benefits
has been firmly established. The second agent, arginine butyrate
has the potential for beneficial effects via two routes, it makes
arginine available as a substrate for nNOS, while the butyrate
moiety modifies histones and has widespread effects on gene
expression. Here again, the range of potential effector pathways is
open to speculation. Our results from evaluating these two agents
vindicates our general approach, for we have picked up quite
different sets of benefits and dis-benefits from the two treatments,
none of which would have been predictable from the existing
literature on their biological effects.
In this study, we have taken a comprehensive approach to
evaluating the effects of 6 months administration of arginine
butyrate, prednisone, and a combination of both drugs on the
disease phenotype in mdx mice. Our data indicate that 6 months
administration of arginine butyrate is well tolerated by the mdx
mice. We noted a decrease in fibrosis in the skeletal muscle, which
correlated well with improvements in grip strength. Furthermore,
gene expression profiling of arginine butyrate-treated skeletal
muscle indicated an increase in growth-promoting pathways (e.g.,
the IGF-1 pathway) and a decrease in pro-fibrotic pathways. We
did not see any significant differences in behavioral activity,
Rotarod performance, histology, or serum CK levels between the
Figure 7. Effect of treatments on utrophin expression in
skeletal muscle. Muscle lysates from gastrocnemius muscle were
analyzed by Western blotting using anti-utrophin antibody. Beta-
tubulin expression was assessed on the same blot as a loading control.
The autoradiograms were scanned, and volume analysis was carried out
using Quantity One software. The ratios of utrophin to beta-tubulin
were calculated for all groups. Error bars indicate +/2 1 SD. **p=,0.01.
doi:10.1371/journal.pone.0011220.g007
Figure 8. Effect of treatments on gene expression profiling. Temporal clustering of transcriptomes in arginine butyrate-, prednisone- and
combination-treated mice and saline-treated controls. Signals were processed using the PLIER algorithm. Unsupervised hierarchical clustering
(p,0.01) was done using GeneSpring Software (GeneSpring GX, Fostercity, CA). The data was normalized to the saline treated controls; yellow
indicates normal; blue indicated decreased expression and red indicated increased expression of genes.
doi:10.1371/journal.pone.0011220.g008
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However, prednisone and combination treated groups showed
significant alterations in genes that affect fibrosis, inflammation
and myogenesis. This data is consistent with loss of body weight,
poor performance on functional and behavioral measures, and
decrease in cardiac function and increase in fibrosis.
Since body weight is a simple measure of the overall drug effect
on the mouse phenotype, we measured body weight at different
times during the trial and found that arginine butyrate had no
significant effect on body weight, with arginine butyrate-treated
mice showing a growth pattern indistinguishable from that of
saline-treated mice. In contrast, prednisone-treated (1 mg/kg/day)
with or without combination drug-treated mice showed a
significant decrease in body weight. This prednisone-induced
decrease in body weight and reduction of weight gain in mdx mice
has also been noted in previous studies [8,9]. It appears that
normalized soleus mass is increased in all treated groups indicating
some degree hypertrophy on the other hand normalized heart
mass significantly increased in prednisone and combination
treated groups suggesting an increase in cardiomyopathy. Overall
these data clearly demonstrate that 6 months administration of
arginine butyrate is safe and that chronic continuous administra-
tion of prednisone is catabolic to dystrophic muscle and
combination is clearly immunosuppressive as reflected by the
spleen size. The molecular mechanisms underlying this differential
catabolic effect on different tissues and muscle groups are currently
being investigated.
Grip strength has been extensively used to evaluate drug effects
in the mdx mouse model [10,11,12,13,14,15]. Absolute forelimb
and hindlimb strengths (unadjusted body weight) for the arginine
butyrate-treated group at all ages appeared to be greater than
those of the other drug treatment groups, suggesting that arginine
butyrate treatment improves forelimb and hindlimb strength.
Since there was a significant body weight difference between these
mice and the prednisone- and combination-treated mice, we
normalized the grip strength values to the body weight. Although
the arginine butyrate-treated mice did not show a significant
difference in body weight, they still showed improved forelimb
performance when compared to saline-treated mice. In contrast,
after normalization for body weight the prednisone- and
combination-treated groups showed significantly better forelimb
grip strength because of the decrease in body weight that had
occurred with prednisone treatment. In terms of hindlimb grip
strength, the prednisone- and combination-treated groups showed
a significantly lower level of force than did the arginine butyrate-
or saline-treated mice. The reported effects of prednisone on grip
strength vary widely, with some showing a significant increase
[10,11,16] and others reporting no effect [17,18]. These
differences could reflect differences in the ages of the mice, or
the doses, routes of administration, and/or duration of prednisone
treatment. Our data indicate that there are differences in forelimb
and hindlimb grip strength responses and that the prednisone
effects are more pronounced in the forelimbs than in the
hindlimbs, especially after the results are adjusted for body weight.
Our data clearly demonstrate that decrease in normalized forelimb
and hindlimb grip strength is stabilized in more in prednisone
treated group than arginine butyrate and combination groups.
We also assessed motor coordination using a Rotarod and found
that the ability to stay on the Rotarod decreased significantly with
age. It appears that none of the drugs we tested had a significant
effect on motor coordination under these conditions. We also
assessed the overall behavioral activity of the mice using an open
field Digiscan apparatus and found that the animals adapted to the
Digiscan apparatus over a period of time and generally performed
better with time than they did at the initial time point. A
comparison of the various treatment groups clearly indicated that
the arginine butyrate-treated group generally showed lower
horizontal activity, vertical activity, and total distance traversed
than did the saline-treated group, but the combination-treated
group performed better on all three parameters. The reasons for
this poor performance on open field behavioral activity after
arginine butyrate treatment are unclear; however, the positive
behavioral effects seen with combination group were likely
influenced by their reduced body weight when compared to the
saline-treated mice.
H&E staining of skeletal muscle of treated mice indicated no
significant changes in comparison to saline treated group. It is
unclearly why the improvements in grip strength are reflected in
improvement in histological changes. Since H&E is not useful for
detecting fibrosis, we used Sirius Red, which has been used for
many years to detect fibrosis [19]. We found a trend toward a
decrease in fibrosis in both the skeletal muscle and heart in
arginine butyrate-treated mice. Surprisingly we did not see a
decreasing trend in fibrosis of diaphragm in arginine butyrate-
treated mice. It is currently unclear how different tissues respond
to anti-fibrotic treatments. The trends we observed toward
increases in grip strength and cardiac function, together with the
decrease in fibrosis after arginine butyrate treatment, indicated a
positive effect on skeletal muscle and heart function. Likewise, the
opposite trend seen with the prednisone- and combination-treated
groups suggests that 6 months treatment with prednisone is
detrimental to both skeletal muscle and heart function.
The arginine butyrate treated group have decreased cell size
distribution in comparison to saline treated group probably due to
increase in trend in fibers with central nuclei/field (regeneration)
on the other hand decrease in fiber size is more pronounced in
prednisone and combination treated groups correlating with
increase in trend in the degenerating fibers on H&E sections.
Our results support the finding that L-arginine-treated mdx mice
also show an increased coronary flow and reduced diastolic
stiffness relative to saline-treated mdx mice and that a reduction in
stiffness is associated with a significant reduction in cardiac
collagen. This suggests that chronic treatment with L-arginine is
beneficial in that it improves function and reduces fibrosis in the
dystrophin-deficient heart [20]. Furthermore, recent studies have
also indicated that L-arginine treatment decreases the activity of
NF-kB and metalloproteinases MMP-2 and MMP-9, reduces beta-
dystroglycan cleavage, and causes the translocations of utrophin
and nNOS throughout the sarcolemma, thus promoting muscle
membrane integrity and reducing fibrosis in dystrophic muscle
[21]. It is also known that L-arginine treatment blocks macro-
phage infiltration and the TGF-b1-induced collagen deposition
seen in tubulointerstitial fibrosis [22,23]. Recent studies have also
indicated that L-arginine treatment significantly reduces necrosis
in mdx mouse muscle [21,24,25]. L- arginine reduces sarcolemmal
injury by inducing up-regulation of utrophin and b-dystroglycan
levels and increasing the stability of membrane-associated proteins
such as integrin-alpha7 [26].
Although arginine butyrate has been reported to induce several
fetal genes, we did not see any significant up-regulation of
utrophin in the skeletal muscle of arginine butyrate-treated mice at
either the protein or the mRNA level. In contrast, L-arginine
treatment has previously been shown to induce utrophin
expression in mdx mouse muscle [25,27]. The reasons for this
discrepancy are unclear; they could be related to the fact that we
used arginine butyrate rather than L-arginine. Unlike the results
we obtained for arginine butyrate, we saw more pronounced
utrophin protein expression in the prednisone- and combination-
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of the mdx mouse has previously been shown to stimulate utrophin
A expression in skeletal muscle fibers [28]. Also, a translational
regulatory mechanism involving increased IRES activation has
recently been shown to mediate increased expression of utrophin
A in muscle cells treated with glucocorticoids [29]. These findings
support the notion that one of the mechanisms of glucocorticoid
action is through the stimulation of endogenous utrophin levels in
dystrophic skeletal muscle fibers [30].
Our results indicated that mdx mice generally have higher serum
CK levels than control mice and that this was not affected. One
published study has indicated that L-arginine treatment reduces
serum CK levels [25], and another reported no effect of L-arginine
[27] on mdx mice. Even though the prednisone- and combination-
treated groups showed a trend toward a decrease in serum CK
levels, these changes were not statistically significant. Our data
regarding prednisone are consistent with the reports beneficial
effects on serum CK levels in mdx mice [16].
The butyrate moiety of arginine butyrate has been shown to
inhibit histone deacetylase, resulting in hyperacetylation of
histones H3 and H4. Acetylated histones have a reduced affinity
for chromatin, allowing chromosomal unfolding that can poten-
tially modulate the expression of particular genes, including fetal
forms of adult genes. This situation is consistent with our
observation that 6015 genes were significantly altered in the
arginine butyrate-treated mice, 972 in the prednisone-treated
mice, and 1411 in the combination-treated mice. Our gene
expression profiling data indicate cell proliferation, growth and
differentiation as well as genes that control inflammatory, growth-
promoting fibrotic genes are differentially affected by arginine
butyrate treatment. Genes interacting with collagen deposition,
abnormal inflammatory response and degeneration of fibers
explain fibrotic effects of prednisone on the skeletal muscle.
Likewise combination treated group regulated genes that contrib-
ute to muscle wasting and atrophy by inhibiting myogenesis, cell
proliferation, interrupting cell cycle and impairing sarcolemmal
localization of dystrophin. Further confirmatory experiments are
needed to investigate the differentially affected gene pathways at
protein level.
Overall, arginine butyrate treatment tended to improve grip
strength and decrease fibrosis in the gastrocnemius. These data are
supported by the increase in the expression of growth-promoting
genes and decrease in pro-fibrotic genes that we observed in the
skeletal muscle of arginine butyrate-treated mice. On the other
hand, we did not observe significant changes in muscle histology;
behavioral measurements, heart function or serum CK levels after
arginine butyrate treatment. Detailed experiments need to be
carried out in order to evaluate the effects of arginine butyrate
treatment in younger mice.
In general, our state understanding of the pathological pathways
and our knowledge of the range of possible effects of any given low
molecular weight drug on these complex networks of pathways is
quite superficial. In such circumstances, it is unwise to constrain
analysis to functional effects on the basis of prior expectation based
on our limited understanding of the action of these agents in other
pathologies. The broad empirical approach we have used here has
the merit of increasing the prospects of picking up unexpected
beneficial activities. More importantly, such a broad survey also
increases the probability of identifying unexpected ill effects such
as the increased cardiac fibrosis associated with continuous
administration of prednisone. This study highlights the need for
comprehensive evaluation strategies to detect both beneficial and
harmful effects any drug currently in therapeutic use or for which
therapeutic testing is contemplated.
Supporting Information
Table S1 Comparison of individual muscle and organ weights of
treatments in mdx mice.
Found at: doi:10.1371/journal.pone.0011220.s001 (0.04 MB
DOC)
Table S2 Genes differentially expressed along with fold change.
Found at: doi:10.1371/journal.pone.0011220.s002 (0.07 MB
PDF)
Figure S1 Effect of 6 months treatment on behavioral assays: A)
Rotarod testing. Open field activity (Digiscan)-B) horizontal
activity. The combination-treated group (broken grey) showed a
smaller increase in horizontal activity than did the arginine
butyrate-treated (solid grey), prednisone-treated (broken black), or
saline control (solid black) groups. The arginine butyrate-treated
group showed less activity than did the rest of the groups. C)
Vertical activity. All the groups except the arginine butyrate-
treated group showed a progressive increase in their vertical
activity. The arginine butyrate-treated group showed a decrease in
vertical activity from baseline (3 months of age) to (5 months of
age); the activity increased later but never reached that of the other
groups. D) Total distance. While the saline-treated group showed a
progressive increase in the total distance over the entire 6 months
of treatment, the drug-treated groups demonstrated an erratic
pattern. The arginine butyrate-treated group showed a decline
toward the second month of treatment and recovery when
compared to baseline at the end of the trial, with a statistically
significant difference from the levels for the prednisone-treated
group at 5 months of age. The prednisone-treated group did not
change significantly during the trial. The combination-treated
group showed an overall increase, with a small reduction at 7
months of age.
Found at: doi:10.1371/journal.pone.0011220.s003 (4.29 MB TIF)
Figure S2 Fiber size distribution was evaluated by laminin
immunoflourescence and minimal feret measurements. The data
were ranked and normalized to sample size (rank number/total
sample number). Normalized rank was plotted on the vertical axis
against fiber size on the horizontal axis. Treatment groups: saline
(blue), arginine butyrate (red), prednisone (green), a combination
of arginine butyrate and prednisone (grey).
Found at: doi:10.1371/journal.pone.0011220.s004 (3.28 MB TIF)
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